Article PDF
Change history
09 September 2010
The original version of this article misstated the development status of GenKyoTex S.A.'s NOX2 inhibitors in Box 1, "NOX2-driven schizophrenia" and has been updated.
Additional information
The online version of the original article can be found at 10.1038/scibx.2010.1043
The online version of the original article can be found at 10.1038/scibx.2010.1045
Rights and permissions
About this article
Cite this article
Fulmer, T. Ketamine meets mTOR. Science-Business eXchange 3, 1032 (2010). https://doi.org/10.1038/scibx.2010.1032
Issue Date:
DOI: https://doi.org/10.1038/scibx.2010.1032